Modella AI and AstraZeneca Partner to Accelerate AI-Driven Oncology Drug Development
Modella AI partners with AstraZeneca to accelerate oncology clinical trials using multi-modal AI foundation models. This collaboration aims to improve biomarker discovery and patient outcomes.
Modella AI and AstraZeneca Partner to Speed Up AI-Driven Oncology Clinical Development
Boston, July 2, 2025 – Modella AI, a leader in AI for life sciences, has entered a multi-year agreement with AstraZeneca. Modella AI will provide AstraZeneca access to its multi-modal AI foundation models, designed to extract detailed features from various data types. This collaboration intends to accelerate clinical development within AstraZeneca’s global oncology programs.
Modella AI’s CEO, Jill Stefanelli, highlighted the significance of foundation models in precision medicine. She explained that these models serve as the backbone for AI-driven biomedical discovery and represent a step toward autonomous AI agents. By integrating these models with AstraZeneca’s research capabilities, the companies expect to speed up data-driven development and automate complex research workflows.
How AstraZeneca Will Benefit
AstraZeneca plans to use Modella AI’s platform to enhance oncology research and development with a focus on:
- Accelerating clinical trial timelines
- Discovering new biomarkers
- Improving patient outcomes through data-driven insights
The integration will allow AstraZeneca to scale up its AI-powered discovery processes, improving both speed and accuracy in oncology clinical trials.
According to Jorge Reis-Filho, Chief AI and Data Scientist at AstraZeneca Oncology R&D, AI is already embedded across their clinical development processes. He emphasized that combining foundation models with AstraZeneca’s unique datasets and AI expertise will increase success rates in oncology trials.
About Modella AI
Modella AI is a Boston-based biomedical AI company focused on advancing healthcare through generative and agentic AI technologies. Their expertise spans artificial intelligence and pathology, aiming to create solutions that empower clinicians, improve patient care, and optimize medical workflows.
For more information, visit Modella AI.
Disclaimer: This announcement may include forward-looking statements based on current assumptions. Modella AI does not assume any obligation to update these statements in response to future events.
